24,749 Shares in Pfizer Inc. (NYSE:PFE) Bought by Hoxton Planning & Management LLC

Key Points

• Hoxton Planning & Management LLC has acquired a new position in Pfizer, purchasing 24,749 shares valued at approximately $627,000 during the 1st quarter.
• Pfizer's recent quarterly earnings report showed earnings per share of $0.92, beating the consensus estimate, but its revenue was down 7.8% year-over-year.
• The company declared a quarterly dividend of $0.43 per share with a yield of 7.22%, despite a high dividend payout ratio of 124.64%.

Hoxton Planning & Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 24,749 shares of the biopharmaceutical company's stock, valued at approximately $627,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pacer Advisors Inc. grew its stake in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares in the last quarter. Starboard Value LP purchased a new position in shares of Pfizer during the 4th quarter worth about $407,730,000. Assenagon Asset Management S.A. boosted its stake in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. lifted its holdings in Pfizer by 1,106.0% during the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock valued at $143,967,000 after buying an additional 5,153,257 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PFE shares. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Leerink Partners reduced their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Bank of America boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, BMO Capital Markets reduced their price target on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $28.28.

Pfizer Stock Performance

NYSE:PFE traded up $0.20 during trading hours on Friday, hitting $23.49. 51,287,529 shares of the company were exchanged, compared to its average volume of 38,018,180. The stock has a market capitalization of $133.55 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.84 and a beta of 0.52. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company's 50 day moving average price is $24.36 and its 200-day moving average price is $24.60.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.